Mountain Valley MD (TSE:MVMD)
:MVMD
Top Page
Mountain Valley MD
(MVMD)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.08
▲(295.00% Upside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by weak financial performance (minimal/declining revenue, large losses, and ongoing cash burn with a much smaller equity cushion). Technicals are a partial offset with strong price momentum above key moving averages, but overbought readings add near-term risk. Valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Minimal leverage / low debt
Effectively zero reported debt materially reduces bankruptcy and interest-rate risk for a small biotech. Low leverage preserves financial optionality for R&D or partnerships over months ahead, allowing management to prioritize development or licensing without heavy fixed financing costs.
Negative Factors
Persistent cash burn and negative FCF
Consistent negative operating and free cash flow (~-C$3.9M in 2025) signals ongoing cash consumption that cannot be self-funded. Over a multi-month horizon this increases reliance on external financing, which can dilute shareholders and constrain strategic options if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal leverage / low debt
Effectively zero reported debt materially reduces bankruptcy and interest-rate risk for a small biotech. Low leverage preserves financial optionality for R&D or partnerships over months ahead, allowing management to prioritize development or licensing without heavy fixed financing costs.
Read all positive factors
Mountain Valley MD (MVMD) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$28.19M
Dividend YieldN/A
Average Volume (3M)205.59K
Price to Earnings (P/E)―
Beta (1Y)-0.73
Revenue Growth-46.59%
EPS Growth8.26%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,354,950
10 Day Avg. Volume152,980
30 Day Avg. Volume205,595
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.44
Price to Sales (P/S)177.77
P/FCF Ratio-2.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mountain Valley MD Business Overview & Revenue Model
Company Description
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical...
How the Company Makes Money
null...
Mountain Valley MD Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.00K | 49.00K | 60.00K | 0.00 | 110.00K | 0.00 |
| Gross Profit | 18.00K | 49.00K | -346.00K | -446.00K | 70.00K | -430.19K |
| EBITDA | -1.22M | -3.16M | -2.78M | -6.89M | -9.29M | -4.77M |
| Net Income | -5.96M | -7.47M | -7.67M | -7.44M | -9.71M | -8.14M |
Balance Sheet | ||||||
| Total Assets | 594.00K | 2.74M | 8.97M | 16.77M | 25.27M | 31.61M |
| Cash, Cash Equivalents and Short-Term Investments | 316.00K | 1.72M | 5.92M | 9.71M | 14.22M | 19.51M |
| Total Debt | 89.00K | 0.00 | 0.00 | 6.00K | 44.00K | 84.00K |
| Total Liabilities | 130.00K | 209.00K | 258.00K | 591.00K | 422.00K | 1.11M |
| Stockholders Equity | 464.00K | 2.53M | 8.71M | 16.18M | 24.85M | 30.50M |
Cash Flow | ||||||
| Free Cash Flow | -1.07M | -3.91M | -3.80M | -4.85M | -5.68M | -4.31M |
| Operating Cash Flow | -1.07M | -3.90M | -3.30M | -4.79M | -5.59M | -3.86M |
| Investing Cash Flow | 187.00K | -290.00K | -503.00K | 1.89M | -98.00K | -149.00K |
| Financing Cash Flow | 89.00K | 0.00 | -6.00K | -1.60M | 395.00K | 21.78M |
Mountain Valley MD Technical Analysis
Positive
0.02
Price Trends
0.03
Positive
0.02
Positive
0.02
Positive
Market Momentum
0.02
Negative
82.30
Negative
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 82.30 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MVMD.
Mountain Valley MD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$28.19M | -1.56 | -461.32% | ― | -46.59% | 8.26% | |
47 Neutral | C$16.74M | -4.56 | 899.59% | ― | ― | -80.42% | |
47 Neutral | C$20.21M | -2.55 | ― | ― | -100.00% | -8.70% | |
45 Neutral | C$8.46M | 5.19 | ― | ― | 15.64% | 58.47% | |
42 Neutral | C$2.07M | -10.76 | -11.42% | ― | -5.87% | -239.53% | |
40 Underperform | C$1.95M | -1.54 | -271.33% | ― | 15.95% | -1.81% |
* Healthcare Sector Average
TSE:MVMD
Mountain Valley MD
0.08
0.05
166.67%
TSE:AYUR
Ayurcann Holdings Corp.
0.01
-0.02
-66.67%
TSE:RVV
Revive Therapeutics
0.04
0.02
100.00%
TSE:PCLO
PharmaCielo
0.06
-0.03
-35.29%
TSE:CANB
CanadaBis Capital
0.02
-0.08
-83.33%
TSE:LOBE
Lobe Sciences
0.08
0.03
87.50%
Mountain Valley MD Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Mountain Valley MD to Raise $2 Million and Wipe Out Debt via Equity Deals
Positive
Mar 31, 2026
Mountain Valley MD Holdings plans a non-brokered private placement of up to 80,000,000 units at $0.025 each to raise as much as $2 million from biotech investors, with each unit comprising one common share and a warrant exercisable at $0.08 for 12...
Business Operations and StrategyProduct-Related Announcements
Mountain Valley MD Details Year-End Commercialization Gains Across Core Platforms
Positive
Jan 6, 2026
Mountain Valley MD issued a year-end update highlighting commercialization progress across its three main platforms, with management emphasizing disciplined execution in product development, field validation and commercial foundations as the busin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.